InsidersTradesSigma
Track the Vanda Pharmaceuticals Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vanda Pharmaceuticals Inc. has recorded 126 reports. Market capitalisation: €322.3m. The latest transaction was filed on 8 June 2026 (Attribution). Among the most active insiders: Polymeropoulos Mihael Hristos. Every trade is openly available.
126
Insider Decl.
n/a
Thresholds
€359,570
10 ops.
Buy Volume
€4m
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vanda Pharmaceuticals Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$14.13.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,421 of 29,063 companies
27.5
score / 100
Value5
Quality50
FCF yld-35%
Earn yld-69%
EV/EBITDA·
ROE-78%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 June 2026
Declarations126 total
41,600 shares0Common StockSEC:0001193125-26-261811:0
41,600 shares0Common StockSEC:0001193125-26-261806:0
41,600 shares0Common StockSEC:0001193125-26-261800:0
57,101 shares0Common StockSEC:0002130896-26-000008:0
42,442 shares@ US$8.265943.3% of flowCommon StockSEC:0001806596-26-000002:0
30,800 shares@ US$8.265946.2% of flowCommon StockSEC:0001785888-26-000002:0
42,434 shares@ US$8.265940.6% of flowCommon StockSEC:0001748392-26-000002:0
42,431 shares@ US$8.265958.5% of flowCommon StockSEC:0001702031-26-000002:0
156,235 shares@ US$8.173440.4% of flowCommon StockSEC:0001355537-26-000002:0
30,000 shares@ US$8.03100.0% of flowCommon StockSEC:0001193125-26-067185:0
125,000 shares0Common StockSEC:0001193125-26-059792:0
125,000 shares0Common StockSEC:0001193125-26-059784:0
125,000 shares0Common StockSEC:0001193125-26-059781:0
125,000 shares0Common StockSEC:0001193125-26-059778:0
525,000 shares0Common StockSEC:0001193125-26-059770:0
10,000 shares@ US$4.152.2% of flowCommon StockSEC:0000950170-25-105819:0
Canonical exit: 5 Nov 2025 (T+90)
7,000 shares@ US$4.5913.8% of flowCommon StockSEC:0000950170-25-087025:0
59,225 shares0Common StockSEC:0000950170-25-083890:0
59,225 shares0Common StockSEC:0000950170-25-083889:0
59,225 shares0Common StockSEC:0000950170-25-083888:0
59,225 shares0Common StockSEC:0000950170-25-083885:0
59,225 shares0Common StockSEC:0000950170-25-083884:0
9,519 shares@ US$4.401.9% of flowCommon StockSEC:0000950170-25-076012:0
Canonical exit: 19 Aug 2025 (T+90)
20,000 shares@ US$4.22364.0% of flowCommon StockSEC:0000950170-25-074565:0
Canonical exit: 14 Aug 2025 (T+90)
5,000 shares@ US$5.021.2% of flowCommon StockSEC:0000950170-25-034966:0
Canonical exit: 4 Jun 2025 (T+90)
25 of 126 declarations
关于 Vanda Pharmaceuticals Inc.
从竞争角度来看，Vanda 在竞争激烈的专业市场中运营，其差异化取决于临床疗效、安全性、知识产权保护和商业执行力。该公司专注于利基治疗领域而非大众市场，如果产品成功上市，这可以支持可观的利润，但同时也增加了与 FDA 决策和临床试验结果相关的二元风险。近期 2026 年的公开更新强调了 imsidolimab 的监管进展和 NEREUS 在美国的商业发布，同时也表明某些与 HETLIOZ 相关的监管请求面临不利结果。因此，对于投资者而言，Vanda 看起来是一家具有高风险/回报特征的医疗保健公司，对 FDA 催化剂、Fanapt 销售势头以及公司将其研发管线转化为经常性收入的能力高度敏感。
